Cargando…

14.3 Early cardiovascular risk assessment in patients with juvenile idiopathic arthritis

Detalles Bibliográficos
Autores principales:	Vlahos, AP, Alfantaki, S, Bechlioulis, A, Vakalis, K, Michalis, LK, Siamopoulou, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334188/ http://dx.doi.org/10.1186/1546-0096-6-S1-S30

Ejemplares similares

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
por: Hunter, PJ, et al.
Publicado: (2008)

Juvenile idiopathic arthritis-associated uveitis: Data from a region in western Greece
por: Asproudis, Ioannis, et al.
Publicado: (2010)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Whole exome sequencing in systemic juvenile idiopathic arthritis
por: Moghaddas, F, et al.
Publicado: (2015)

3.4 Physical activity in adolescents with juvenile idiopathic arthritis
por: Lelieveld, OTHM, et al.
Publicado: (2008)

Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis
por: Zholobova, Elena, et al.
Publicado: (2014)

14.5 Rheumatoid Arthritis susceptibility loci; STAT4, TRAF1/C5 and 6q23 region, are also associated with Juvenile Idiopathic Arthritis
por: Hinks, A, et al.
Publicado: (2008)

Juvenile idiopathic arthritis is associated with potentially pathogenic glycosylation of IgG
por: Ercan, Altan, et al.
Publicado: (2012)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, Pieter E H, et al.
Publicado: (2011)

Monocytes and neutrophils in the inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis
por: ter Haar, N, et al.
Publicado: (2015)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

Patients with early-onset systemic juvenile idiopathic arthritis show more inflammation and worse outcome
por: Russo, R, et al.
Publicado: (2011)

3.5 Comparison of functional ability in juvenile idiopathic arthritis, juvenile dermatomyositis, juvenile systemic lupus erythematosus and healthy controls. An analysis of the PRINTO database
por: Filocamo, G, et al.
Publicado: (2008)

Preliminary study of regionalised centre-of-pressure analysis in patients with juvenile idiopathic arthritis
por: Hendry, Gordon J, et al.
Publicado: (2012)

Musculoskeletal ultrasound versus magnetic resonance in supporting clinical management of juvenile idiopathic arthritis
por: Lanni, Stefano, et al.
Publicado: (2014)

Systemic juvenile idiopathic arthritis is associated with HLA-DRB1 in Europeans and Americans of European descent
por: Ombrello, Michael, et al.
Publicado: (2012)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2011)

2.4 Magnetic resonance imaging, ultrasonography and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis
por: Malattia, C, et al.
Publicado: (2008)

The risk and nature of flares in juvenile idiopathic arthritis: results from the reACCh-Out cohort
por: Guzman, Jaime, et al.
Publicado: (2014)

Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Minoia, Francesca, et al.
Publicado: (2014)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

Safety and efficacy of ultrasound guided corticosteroid injections into temporomandibular joints in children with active juvenile idiopathic arthritis
por: Habibi, S, et al.
Publicado: (2011)

Two year remission rates and functional outcomes in an inception cohort of Canadian children with juvenile idiopathic arthritis
por: Tse, Shirley ML, et al.
Publicado: (2012)

YIM-O13. Development of novel protein biomarkers for the prediction of response to treatment in juvenile idiopathic arthritis
por: Palman, Jason, et al.
Publicado: (2014)

7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis
por: Ruperto, N, et al.
Publicado: (2008)

A Greek multicenter study comparing the clinical and immunologic phenotypes between adult and juvenile- onset lupus
por: Nalbanti, P, et al.
Publicado: (2011)

Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Davì, Sergio, et al.
Publicado: (2011)

SpineCore treatment for juvenile idiopathic scoliosis
por: Coillard, Christine, et al.
Publicado: (2010)

4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
por: Hinze, CH, et al.
Publicado: (2008)

Frequent discordance between clinical and musculoskeletal ultrasound examinations of foot disease in juvenile idiopathic arthritis observed in the multidisciplinary setting
por: Hendry, Gordon J, et al.
Publicado: (2011)

Application of a novel multi-segment foot model to assess foot function in children and adolescents with juvenile idiopathic arthritis
por: Hendry, Gordon J, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

OA31 Successes and challenges in harmonising 4 national Juvenile Idiopathic Arthritis cohorts: an example from CLUSTER consortium
por: Lawson-Tovey, Saskia, et al.
Publicado: (2022)

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
por: De Benedetti, F, et al.
Publicado: (2014)

14.2 Causes of early death in juvenile onset systemic lupus erythematosus (JSLE)
por: Bader-Meunier, B, et al.
Publicado: (2008)

Regulatory T cells from the inflamed joints of patients with juvenile idiopathic arthritis (JIA) are dysregulated and display a pro-inflammatory profile
por: Pesenacker, AM, et al.
Publicado: (2011)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis
por: Ombrello, M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ir19j7avk0srji924rmkh9l67t